BioCentury

7:00 AM GMT, Apr 8, 2013
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Emerging Company Profile

Ziarco: Scratching the allergic itch

Ziarco Pharma Ltd. emerged last year from a shuttered Pfizer Inc. R&D site in Sandwich, U.K., with a quartet of allergy and inflammation assets that otherwise would have been shelved and forgotten. The biotech's lead program for steroid-refractory atopic dermatitis could avoid toxicity issues that sidelined a competing program and could be first in class for the indication.

Last November, Ziarco in-licensed exclusive, worldwide rights to the assets. Pfizer received an equity stake and is eligible for milestones, plus royalties. Ziarco co-founder, President and

Read the full 832 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.